Ser1231

Site Information
GCARLGQsPPGRGGL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 25174228

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	leukemia ( 5 ) , acute myelogenous leukemia ( 5 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:	H2077 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HeLa (cervical) ( 3 ) , Jurkat (T lymphocyte) ( 2 ) , KG-1 (myeloid) ( 5 ) , NCI-H2030 (pulmonary) ( 4 ) , SH-SY5Y (neural crest) ( 1 )

References
1	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
2	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info